Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation, Multiple-Dose Escalation, and Food Effect Study of FLX475 in Healthy Male and Female Subjects

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation, Multiple-Dose Escalation, and Food Effect Study of FLX475 in Healthy Male and Female Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2018

At a glance

  • Drugs FLX-475 (Primary)
  • Indications Cancer
  • Focus Adverse reactions; First in man
  • Sponsors FLX Bio
  • Most Recent Events

    • 08 Nov 2018 Results presented in the FLX Bio media release.
    • 08 Nov 2018 According to an FLX Bio media release, data from this trial will be presented on November 10, 2018 at the Society for Immunotherapy of Cancer Meeting in Washington D.C.
    • 21 Dec 2017 According to an FLX Bio media release, the first subject has been dosed in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top